Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Qualcomm Inc.

Start price
Target price
Perf. (%)
€123.94
31.08.21
€135.00
31.08.22
9.81%
04.11.21

Innovative
Some uniques
Top 10 in its market
EBIT growth >5% per year expected
buy
Qualcomm Inc.

Start price
Target price
Perf. (%)
€123.94
31.08.21
€135.00
31.08.22
9.81%
04.11.21

Innovative
Some uniques
Top 10 in its market
EBIT growth >5% per year expected
buy
Qualcomm Inc.

Start price
Target price
Perf. (%)
€123.94
31.08.21
€135.00
31.08.22
9.81%
04.11.21

Innovative
Some uniques
Top 10 in its market
EBIT growth >5% per year expected
buy
Aixtron SE

Start price
Target price
Perf. (%)
€26.21
31.08.21
-
31.08.22
-12.25%
31.08.22

buy
Aixtron SE

Start price
Target price
Perf. (%)
€26.21
31.08.21
-
31.08.22
-12.25%
31.08.22

buy
Qualcomm Inc.

Start price
Target price
Perf. (%)
€123.94
31.08.21
-
31.08.22
10.74%
31.08.22

buy
Qualcomm Inc.

Start price
Target price
Perf. (%)
€123.94
31.08.21
-
31.08.22
10.74%
31.08.22

buy
Qualcomm Inc.

Start price
Target price
Perf. (%)
€123.94
31.08.21
-
31.08.22
10.74%
31.08.22

buy
Hypoport SE

Start price
Target price
Perf. (%)
€593.50
31.08.21
-
31.08.22
-67.67%
31.08.22

buy
MorphoSys AG

Start price
Target price
Perf. (%)
€47.81
30.08.21
€53.00
30.08.22
5.67%
04.09.21

Could be worthwhile Investment >10% per year
Innovative
Top 10 in its market
Higher risks for its business
buy
MorphoSys AG

Start price
Target price
Perf. (%)
€47.81
30.08.21
€53.00
30.08.22
5.67%
04.09.21

Could be worthwhile Investment >10% per year
Innovative
Top 10 in its market
Higher risks for its business
buy
K+S AG

Start price
Target price
Perf. (%)
€12.18
30.08.21
€22.99
28.09.23
38.83%
28.09.23

Could be very worthwhile Investment >20% year
buy
Moderna Inc.

Start price
Target price
Perf. (%)
€323.05
30.08.21
€450.00
31.12.23
-61.76%
08.05.23

Could be very worthwhile Investment >20% year
buy
MacroGenics Inc.

Start price
Target price
Perf. (%)
€20.41
30.08.21
€40.00
31.12.23
-16.71%
07.09.21

Could be very worthwhile Investment >20% year
buy
ProQR Therapeutics N.V.

Start price
Target price
Perf. (%)
€5.65
30.08.21
€12.00
31.12.23
-66.02%
08.05.23

Could be very worthwhile Investment >20% year
buy
Horizon Pharma plc

Start price
Target price
Perf. (%)
€92.84
30.08.21
€200.00
31.12.23
8.36%
08.05.23

Could be very worthwhile Investment >20% year
buy
Cytokinetics Inc.

Start price
Target price
Perf. (%)
€28.20
30.08.21
€50.00
31.12.23
63.83%
28.06.22

Could be very worthwhile Investment >20% year
buy
Curis Inc.

Start price
Target price
Perf. (%)
€7.08
30.08.21
€30.00
31.12.23
-89.90%
08.05.23

Could be very worthwhile Investment >20% year
buy
Celldex Therapeutics

Start price
Target price
Perf. (%)
€43.66
30.08.21
€110.00
31.12.23
-31.75%
08.05.23

Could be very worthwhile Investment >20% year
buy
Chimerix Inc.

Start price
Target price
Perf. (%)
€6.13
30.08.21
€12.00
31.12.23
-83.13%
08.05.23

Could be very worthwhile Investment >20% year
buy
Protagonist Therapeutics Inc

Start price
Target price
Perf. (%)
€39.00
30.08.21
€70.00
31.12.23
-61.03%
08.05.23

Could be very worthwhile Investment >20% year
buy
Ocular Therapeutix Inc.

Start price
Target price
Perf. (%)
€9.30
30.08.21
€30.00
31.12.23
-33.87%
22.10.21

Could be very worthwhile Investment >20% year
buy
Larimar Therapeutics Inc.

Start price
Target price
Perf. (%)
€11.70
30.08.21
€30.00
31.12.23
-63.93%
08.05.23

Could be very worthwhile Investment >20% year
buy
Tencent Holdings Ltd.

Start price
Target price
Perf. (%)
€50.01
29.08.21
-
29.08.22
-14.12%
05.07.22

Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
EBIT growth >5% per year expected
Small challenges to pay loans and raise capital
buy
Tencent Holdings Ltd.

Start price
Target price
Perf. (%)
€50.01
29.08.21
-
29.08.22
-14.12%
05.07.22

Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
EBIT growth >5% per year expected
Small challenges to pay loans and raise capital